RTS,S/AS02A for malaria

Expert Review of Vaccines

Volumn 5, Issue 5, 2006, Pages 611-615

  Bojang, Kalifa A ^a  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

Author keywords

Circumsporozoite protein; Clinical trial; Malaria vaccine

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTIMALARIAL AGENT; ARTEMISININ; CELL SURFACE PROTEIN; CIRCUMSPOROZOITE PROTEIN; DIPLOID CELL VACCINE; FANSIDAR; HEPATITIS B SURFACE ANTIGEN; IMMUNOSTIMULATING AGENT; INTRALIPID; MALARIA VACCINE; MALARIA VACCINE RTS S; PHOSPHORYL LIPID A; PLACEBO; SPOROZOITE VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; CHILD HEALTH CARE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FORMULATION; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MALARIA; NONHUMAN; PLASMODIUM FALCIPARUM; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ADJUVANTS, IMMUNOLOGIC; AFRICA SOUTH OF THE SAHARA; ANIMALS; CHILD; CHILD, PRESCHOOL; ENDEMIC DISEASES; ERYTHROCYTES; HUMANS; IMMUNIZATION SCHEDULE; INFANT; MALARIA VACCINES; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; RANDOMIZED CONTROLLED TRIALS; TROPICAL MEDICINE;

EID: 33845884042     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.5.5.611     Document Type: Review

References (35)

1. Rogan WJ, Chen A. Health risks and benefits of bis (4-chlorophenyl)-1,1, 1-trichloroethane (DDT). Lancet 366, 763-773 (2005).
2. Lengeler C. Insecticide-treated bednets and curtains for preventing malaria. Cochrane Database Syst. Rev. 2, CD000363 (2000).
3. Greenwood BM, Bojang K, Whitty CJ, Targett GA. Malaria. Lancet 365, 1487-1498 (2005).
4. Sachs J, Malaney P. The economic and social burden of malaria. Nature 415, 680-685 (2002).
5. Hoffman SL, Goh LM, Luke TC et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J. Infect. Dis. 185, 1155-1164 (2002).
6. Webster D, Hill A. Progress with new malaria vaccines. Bull. World Health Organ. 81, 902-909 (2003)
7. Hoffman SL, Isenbarger D, Long GW et al. Sporozoite vaccine induces genetically restricted T cell elimination of malaria from hepatocytes. Science 244, 1078-1081 (1989).
8. Hill AV. Pre-erythrocytic malaria vaccines: towards greater efficacy. Nat. Rev. Immunol. 6, 21-32 (2006).
9. Luke TC, Hoffman SL. Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J. Exp. Biol. 206, 3803-3808 (2003).
10. Dame JB, Williams JL, McCutchan TF et al. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science 225(4662), 593-599 (1984).
11. Burkot TR, Da ZW, Geysen HM, Wirtz RA, Saul A. Fine specificities of monoclonal antibodies against the Plasmodium falciparum circumsporozoite protein: recognition of both repetitive and non-repetitive regions. Parasite Immunol. 13, 161-170 (1991).
12. Herrington DA, Clyde DF, Losonsky G et al. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 328, 257-259 (1987).
13. Ballou WR, Hoffman SL, Sherwood JA et al. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet 1(8545), 1277-1281 (1987).
14. Sherwood JA, Oster CN, Adoyo-Adoyo M et al. Safety and immunogenicity of a Plasmodium falciparum sporozoite vaccine: boosting of antibody response in a population with prior natural exposure. Trans. R. Soc. Trop. Med. Hyg. 85, 336-340 (1991).
15. Sherwood JA, Copeland RS, Taylor KA et al. Plasmodium falciparum circumsporozoite vaccine immunogenicity and efficacy trial with natural challenge quantitation in an area of endemic human malaria of Kenya. Vaccine 14(8), 817-827 (1996).
16. Brown AE, Singharaj P, Webster HK et al. Safety, immunogenicity and limited efficacy study of a recombinant Plasmodium falciparum circumsporozoite vaccine in Thai soldiers. Vaccine 12, 102-108 (1994).
17. Vreden SGS, Verhave JP, Oettinger T, Sauerwein RW, Meuwissen JH. Phase I clinical trial of a recombinant malaria vaccine consisting of the circumsporozoite repeat region of Plasmodium falciparum coupled to hepatitis B surface antigen. Am. J. Trop. Med. Hyg. 45, 533-538 (1991).
18. Heppner DG Jr, Kester KE, Ockenhouse KF et al. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine 23, 2243-2250 (2005).
19. Gordon DM, McGovern TW, Krzych U et al. Safety, immunogenicity and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein/HBsAg subunit vaccine. J. Infect. Dis. 171, 1576-1585 (1995).
20. Garcon N, Heppner DG, Cohen J. Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant. Expert Rev. Vaccines 2(2), 231-238 (2003).
21. Ballou WR, Kester KE, Heppner DG. Pre-erythrocytic malaria vaccines to prevent Plasmodium falciparum malaria. Chem. Immunol. 80, 253-261 (2002).
22. Stoute JA, Slaoui M, Heppner DG et al. A preliminary evaluation of a recombinant circumsporozoite protein malaria vaccine against Plasmodium falciparum. N. Engl. J. Med. 336, 86-91 (1997). •• First demonstration of significant efficacy of RTS,S/AS02A in malaria-naïve volunteers.
23. Stoute JA, Kester KE, Krzych U et al. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J. Infect. Dis. 178, 1139-1144 (1998).
24. + T cells producing IFN-γ. J. Immunol. 171(12), 6961-6967 (2003).
25. Kester KE, McKinney DA, Tornieporth N et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J. Infect. Dis. 183(4), 640-647 (2001).
26. Doherty JF, Pinder M, Tornieporth N et al. A Phase I safety and immunogenicity trial with the candidate malaria vaccine, RTS,S/SBAS2, in semi-immune adults in The Gambia. Am. J. Trop. Med. Hyg. 61, 865-868 (1999).
27. Stoute JA, Heppner DG Jr, Mason CJ et al. Phase I safety and immunogenicity trial of malaria vaccine RTS,S/AS02A in adults in a hyperendemic region of western Kenya. Am. J. Trop. Med. Hyg. 75, 166-170 (2006).
28. Bojang KA, Milligan PJ, Pinder M et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358, 1927-1934 (2001). •• First demonstration of efficacy trial of RTS,S/AS02A in an endemic country.
29. Alloueche A, Milligan P, Conway DJ et al. Protective efficacy of the RTS,S/AS02 Plasmodium falciparum malaria vaccine is not strain specific. Am. J. Trop. Med. Hyg. 68, 97-101(2003).
30. Bojang KA, Olodude F, Pinder M et al. Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children. Vaccine 4(23), 4148-4157 (2005). • First demonstration of safety and immunogenicity of RTS,S/AS02A in children.
31. Alonso P, Sacarlal J, Aponte J et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364, 1411-1420 (2004). •• First demonstration of protective efficacy of RTS,S/AS02 in children.
32. Alonso PL, Sacarlal J, Aponte JJ et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomized controlled trial. Lancet 366, 2012-2018 (2005).
33. Stewart VA, McGrath SM, Walsh DS et al. Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A. Vaccine 24(42-43), 6483-6492 (2006).
34. Dunachie SJ, Walther M, Vuola JM et al. A clinical trial of prime-boost immunization with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. Vaccine 5(24), 2850-2859 (2006).
35. Website 101 Final Malaria Vaccine Technology Roadmap www. malariavaccineroadmap.net